These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 11404068

  • 41. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.
    Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF.
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2645-52. PubMed ID: 10991838
    [Abstract] [Full Text] [Related]

  • 42. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections.
    Hoban D, Felmingham D.
    J Antimicrob Chemother; 2002 Sep; 50 Suppl S1():49-59. PubMed ID: 12239228
    [Abstract] [Full Text] [Related]

  • 43. Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis.
    Cormican MG, Erwin ME, Marshall SA, Jones RN.
    Diagn Microbiol Infect Dis; 1996 Mar; 24(3):155-60. PubMed ID: 8724401
    [Abstract] [Full Text] [Related]

  • 44. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E, Dalhoff A, Korfmann G.
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [Abstract] [Full Text] [Related]

  • 45. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment.
    Pfaller MA, Ehrhardt AF, Jones RN.
    Am J Med; 2001 Dec 17; 111 Suppl 9A():4S-12S; discussion 36S-38S. PubMed ID: 11755437
    [Abstract] [Full Text] [Related]

  • 46. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance.
    Boswell FJ, Andrews JM, Jevons G, Wise R.
    J Antimicrob Chemother; 2002 Oct 17; 50(4):495-502. PubMed ID: 12356793
    [Abstract] [Full Text] [Related]

  • 47. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
    Bauernfeind A.
    J Antimicrob Chemother; 1997 Nov 17; 40(5):639-51. PubMed ID: 9421311
    [Abstract] [Full Text] [Related]

  • 48. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN, Pfaller MA, SENTRY Antimicrobial Surveillance Program Participants Group (USA).
    Diagn Microbiol Infect Dis; 2001 Apr 17; 39(4):237-43. PubMed ID: 11404067
    [Abstract] [Full Text] [Related]

  • 49. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
    Piddock LJ, Jin YF.
    J Antimicrob Chemother; 1999 May 17; 43 Suppl B():39-42. PubMed ID: 10382874
    [Abstract] [Full Text] [Related]

  • 50. Selection of resistant variants of respiratory pathogens by quinolones.
    Sefton AM, Maskell JP, Williams JD.
    Int J Antimicrob Agents; 1999 Jul 17; 12(2):129-34. PubMed ID: 10418757
    [Abstract] [Full Text] [Related]

  • 51. Activity of gatifloxacin compared to those of seven agents against bacteria recovered from outpatients with respiratory tract infection.
    Smayevsky J, Lopez H, Di Chiara M, Scarano S, Lanza A, Vilches V, Stepanik D, Bantar C, Sucari A.
    Diagn Microbiol Infect Dis; 2000 Aug 17; 37(4):261-4. PubMed ID: 10974577
    [Abstract] [Full Text] [Related]

  • 52. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
    Esposito S, Noviello S, Ianniello F.
    Chemotherapy; 2000 Aug 17; 46(5):309-14. PubMed ID: 10965095
    [Abstract] [Full Text] [Related]

  • 53. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
    Hoogkamp-Korstanje JA, Dirks-Go SI, Kabel P, Manson WL, Stobberingh EE, Vreede RW, Davies BI.
    J Antimicrob Chemother; 1997 Mar 17; 39(3):411-4. PubMed ID: 9096192
    [Abstract] [Full Text] [Related]

  • 54. Re-evaluation of quality control guidelines for gatifloxacin and garenoxacin (BMS284756) when susceptibility testing Haemophilus influenzae and Streptococcus pneumoniae.
    Anderegg TR, Biedenbach DJ, Jones RN, Quality Control Working Group.
    Diagn Microbiol Infect Dis; 2003 Jun 17; 46(2):147-50. PubMed ID: 12812719
    [Abstract] [Full Text] [Related]

  • 55. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
    Blondeau JM, Suter M, Borsos S.
    J Antimicrob Chemother; 1999 Mar 17; 43 Suppl A():25-30. PubMed ID: 10225568
    [Abstract] [Full Text] [Related]

  • 56. Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance.
    Pérez-Vázquez M, Román F, Varela MC, Cantón R, Campos J.
    J Antimicrob Chemother; 2003 Jan 17; 51(1):147-51. PubMed ID: 12493800
    [Abstract] [Full Text] [Related]

  • 57. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections.
    Casellas JM, Gilardoni M, Tome G, Goldberg M, Ivanovic S, Orduna M, Dolmann A, Ascoli M, Ariza H, Montero JM.
    J Antimicrob Chemother; 1999 Jun 17; 43 Suppl C():37-42. PubMed ID: 10404336
    [Abstract] [Full Text] [Related]

  • 58. Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective.
    Sahm DF, Brown NP, Thornsberry C, Jones ME.
    Postgrad Med; 2008 Sep 17; 120(3 Suppl 1):16-24. PubMed ID: 18931467
    [Abstract] [Full Text] [Related]

  • 59. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
    Kosowska-Shick K, Credito K, Pankuch GA, Lin G, Bozdogan B, McGhee P, Dewasse B, Choi DR, Ryu JM, Appelbaum PC.
    Antimicrob Agents Chemother; 2006 Jun 17; 50(6):2064-71. PubMed ID: 16723567
    [Abstract] [Full Text] [Related]

  • 60. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
    Thornsberry C, Ogilvie P, Kahn J, Mauriz Y.
    Diagn Microbiol Infect Dis; 1997 Dec 17; 29(4):249-57. PubMed ID: 9458982
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.